Novartis Pharma To Add Diagnostics Unit In 2009
This article was originally published in The Gray Sheet
Executive Summary
Novartis' Pharma division will establish a molecular diagnostics unit in 2009, Pharma CEO Joseph Jimenez said during the firm's Nov. 19 R&D day
You may also be interested in...
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Companion Diagnostics Pioneers Explore A Variety Of Business Models
Stakeholders are hoping the regulatory environment for personalized medicine will brighten in the Obama administration, but uncertainty persists about the business case for drug-diagnostics partnerships